GFR-话题@MedSci

#GFR#

483篇内容 | 2605人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534480, encodeId=9ddd15344806f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号, objectType=article, longId=189903, objectId=463418990337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=463418990337, replyNumber=0, likeNumber=62, createdTime=2020-03-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=463418990337, moduleTitle=强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=463418990337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534479, encodeId=20c915344e9a8, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Sci Signal：不同的FGFRs通过不同的配体激活不同的信号通路指导不同的肺部功能发育, objectType=article, longId=189410, objectId=746418941056, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=746418941056, replyNumber=0, likeNumber=65, createdTime=2020-03-07, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=746418941056, moduleTitle=Sci Signal：不同的FGFRs通过不同的配体激活不同的信号通路指导不同的肺部功能发育, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=746418941056)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534478, encodeId=936915344e85f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CLIN CHEM LAB MED：健康女性血清中EGFR和EGFR配体的参考区间, objectType=article, longId=187456, objectId=e67c18e4569a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e67c18e4569a, replyNumber=0, likeNumber=78, createdTime=2020-02-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e67c18e4569a, moduleTitle=CLIN CHEM LAB MED：健康女性血清中EGFR和EGFR配体的参考区间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e67c18e4569a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534477, encodeId=085515344e79b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Clin Oncol：Osimertinib用于携带EGFR罕见突变NSCLC患者的疗效和安全性, objectType=article, longId=185754, objectId=cd71185e5469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd71185e5469, replyNumber=0, likeNumber=70, createdTime=2020-01-07, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd71185e5469, moduleTitle=J Clin Oncol：Osimertinib用于携带EGFR罕见突变NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd71185e5469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534476, encodeId=229815344e66a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Diabetologia：2型糖尿病中eGFR斜率与随后血管结局风险及全因死亡率的关系, objectType=article, longId=185154, objectId=5bca18515448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bca18515448, replyNumber=0, likeNumber=68, createdTime=2019-12-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bca18515448, moduleTitle=Diabetologia：2型糖尿病中eGFR斜率与随后血管结局风险及全因死亡率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bca18515448)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534475, encodeId=a5f315344e5c9, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clinica Chimica Acta：床旁检测尿肌酐测定GFR的肾小球滤过率, objectType=article, longId=185051, objectId=b17618505175, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b17618505175, replyNumber=0, likeNumber=63, createdTime=2019-12-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b17618505175, moduleTitle=Clinica Chimica Acta：床旁检测尿肌酐测定GFR的肾小球滤过率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b17618505175)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534474, encodeId=ad7315344e41c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义, objectType=article, longId=185036, objectId=79b218503619, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79b218503619, replyNumber=0, likeNumber=84, createdTime=2019-12-23, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79b218503619, moduleTitle=Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=79b218503619)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534473, encodeId=16cf15344e3b6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR突变阳性晚期NSCLC一线治疗策略, objectType=article, longId=184327, objectId=4a2618432ef2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a2618432ef2, replyNumber=0, likeNumber=66, createdTime=2019-12-08, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a2618432ef2, moduleTitle=EGFR突变阳性晚期NSCLC一线治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a2618432ef2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534472, encodeId=590615344e2d0, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=NSCLC术后复发转移的诊疗仍有难点，三代EGFR-TKI或可助力突破现状, objectType=article, longId=184136, objectId=38471841368e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=38471841368e, replyNumber=0, likeNumber=73, createdTime=2019-12-05, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=38471841368e, moduleTitle=NSCLC术后复发转移的诊疗仍有难点，三代EGFR-TKI或可助力突破现状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=38471841368e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534471, encodeId=820115344e16e, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=成纤维细胞生长因子受体（FGFR）抑制剂pemigatinib治疗胆管癌获得FDA的优先审查, objectType=article, longId=184090, objectId=d0cc1840903e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0cc1840903e, replyNumber=0, likeNumber=30, createdTime=2019-12-05, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0cc1840903e, moduleTitle=成纤维细胞生长因子受体（FGFR）抑制剂pemigatinib治疗胆管癌获得FDA的优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0cc1840903e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534470, encodeId=fcf515344e0df, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**, objectType=article, longId=183976, objectId=367f1839e6b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=367f1839e6b1, replyNumber=0, likeNumber=61, createdTime=2019-12-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=367f1839e6b1, moduleTitle=长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=367f1839e6b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534469, encodeId=b04f1534469d6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**, objectType=article, longId=183910, objectId=6dfe18391000, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dfe18391000, replyNumber=0, likeNumber=66, createdTime=2019-12-03, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dfe18391000, moduleTitle=从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dfe18391000)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534468, encodeId=2e021534468b3, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=FDA将优先审查Incyte的FGFR抑制剂pemigatinib以治疗胆管癌, objectType=article, longId=183714, objectId=e945183e14f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e945183e14f6, replyNumber=0, likeNumber=66, createdTime=2019-11-29, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e945183e14f6, moduleTitle=FDA将优先审查Incyte的FGFR抑制剂pemigatinib以治疗胆管癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e945183e14f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534467, encodeId=3fd8153446e8a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS, objectType=article, longId=183104, objectId=0beb18310413, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0beb18310413, replyNumber=0, likeNumber=96, createdTime=2019-11-19, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0beb18310413, moduleTitle=JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0beb18310413)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534466, encodeId=3b1015344669c, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=EGFR突变阳性晚期NSCLC的全程管理愈发重要, objectType=article, longId=182628, objectId=4294182628cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4294182628cc, replyNumber=0, likeNumber=69, createdTime=2019-11-10, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4294182628cc, moduleTitle=EGFR突变阳性晚期NSCLC的全程管理愈发重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4294182628cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534465, encodeId=df9e1534465a6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=2019 ESMO：奥希替尼治疗EGFR exon 20ins突变NSCLC再添新证, objectType=article, longId=181109, objectId=276b18110977, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=276b18110977, replyNumber=0, likeNumber=72, createdTime=2019-10-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=276b18110977, moduleTitle=2019 ESMO：奥希替尼治疗EGFR exon 20ins突变NSCLC再添新证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=276b18110977)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534464, encodeId=b4511534464ee, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准, objectType=article, longId=180959, objectId=d44c18095907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d44c18095907, replyNumber=0, likeNumber=72, createdTime=2019-10-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d44c18095907, moduleTitle=贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d44c18095907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534463, encodeId=bef415344638f, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=BMJ：广医附一院何建行教授团队发文：EGFR突变晚期非小细胞肺癌更佳一线治疗方案, objectType=article, longId=180844, objectId=fd6d18084418, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd6d18084418, replyNumber=0, likeNumber=105, createdTime=2019-10-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd6d18084418, moduleTitle=BMJ：广医附一院何建行教授团队发文：EGFR突变晚期非小细胞肺癌更佳一线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd6d18084418)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534462, encodeId=c0531534462fd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC, objectType=article, longId=180839, objectId=78aa180839bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78aa180839bf, replyNumber=0, likeNumber=55, createdTime=2019-10-11, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78aa180839bf, moduleTitle=Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78aa180839bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534461, encodeId=c436153446101, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=2019ESMO|基于ADJUVANT研究建立的MEDUSA模型——将助力EGFR突变早期肺癌术后的精准辅助治疗, objectType=article, longId=180460, objectId=b398180460d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b398180460d6, replyNumber=0, likeNumber=81, createdTime=2019-10-05, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b398180460d6, moduleTitle=2019ESMO|基于ADJUVANT研究建立的MEDUSA模型——将助力EGFR突变早期肺癌术后的精准辅助治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b398180460d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

强生的EGFR-MET双特异性抗体JNJ-6372治疗非小细胞肺癌，获得FDA的突破性疗法称号

2020-03-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Sci Signal：不同的FGFRs通过不同的配体激活不同的信号通路指导不同的肺部功能发育

2020-03-07

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CLIN CHEM LAB MED：健康女性血清中EGFR和EGFR配体的参考区间

2020-02-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Clin Oncol：Osimertinib用于携带EGFR罕见突变NSCLC患者的疗效和安全性

2020-01-07

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Diabetologia：2型糖尿病中eGFR斜率与随后血管结局风险及全因死亡率的关系

2019-12-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clinica Chimica Acta：床旁检测尿肌酐测定GFR的肾小球滤过率

2019-12-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Sci Rep：EGFR-TKIs治疗EGFR突变型非小细胞肺癌的神经生长因子表达及其临床意义

2019-12-23

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR突变阳性晚期NSCLC一线治疗策略

2019-12-08

liuyiping (审核中...)

前往app查看评论内容

#GFR#

NSCLC术后复发转移的诊疗仍有难点，三代EGFR-TKI或可助力突破现状

2019-12-05

liuyiping (审核中...)

前往app查看评论内容

#GFR#

成纤维细胞生长因子受体（FGFR）抑制剂pemigatinib治疗胆管癌获得FDA的优先审查

2019-12-05

liuyiping (审核中...)

前往app查看评论内容

#GFR#

长PFS、长OS、安全性佳、对脑转移疗效佳，奥希替尼或为EGFR突变阳性晚期NSCLC的一线治疗**

2019-12-04

liuyiping (审核中...)

前往app查看评论内容

#GFR#

从规范性、可及性、安全性、疗效综合考虑，奥希替尼可谓EGFR突变阳性晚期NSCLC的一线治疗**

2019-12-03

liuyiping (审核中...)

前往app查看评论内容

#GFR#

FDA将优先审查Incyte的FGFR抑制剂pemigatinib以治疗胆管癌

2019-11-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JAMA Oncol：EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS

2019-11-19

liuyiping (审核中...)

前往app查看评论内容

#GFR#

EGFR突变阳性晚期NSCLC的全程管理愈发重要

2019-11-10

liuyiping (审核中...)

前往app查看评论内容

#GFR#

2019 ESMO：奥希替尼治疗EGFR exon 20ins突变NSCLC再添新证

2019-10-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

贝伐珠单抗（A）联合厄洛替尼（T）与厄洛替尼（T）单药有望成为EGFRm+ NSCLC突变晚期非小细胞肺癌一线治疗新标准

2019-10-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

BMJ：广医附一院何建行教授团队发文：EGFR突变晚期非小细胞肺癌更佳一线治疗方案

2019-10-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Lancet Oncol：埃罗替尼+雷莫芦单抗治疗EGFR突变型转移性NSCLC

2019-10-11

liuyiping (审核中...)

前往app查看评论内容

#GFR#

2019ESMO|基于ADJUVANT研究建立的MEDUSA模型——将助力EGFR突变早期肺癌术后的精准辅助治疗

2019-10-05

科室
- - 订阅+
  - 更多科室
工具
服务